A Phase 1 interventional study of paracervical block and Lidocaine in Abnormal Uterine Bleeding, Analgesia and Paracervical Block, sponsored by Icahn School of Medicine at Mount Sinai. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Icahn School of Medicine at Mount Sinai · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Metrorrhagia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Metrorrhagia · United States.
Among the 43 studies in Metrorrhagia with a site in United States, this one is the 20th largest by planned enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2026, is one of 2 in phase 1, and was the 36th registered.
153 studies on the registry are indexed under Metrorrhagia; 34 are open to participants now.
Browse Metrorrhagia studies →8 of the 43 studies in Metrorrhagia with a site in United States are open now. Recruiting first, the newest first:
Christiana Care Health Services · Sites in United States
Ages 18+ · Women only
Indiana University · Sites in United States
Ages 18+ · Women only
Channel Medsystems · Sites in United States
Ages 25+ · Women only
Eastern Virginia Medical School · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
UConn Health · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Metrorrhagia studies recruiting now, 10 (50%) set no upper age limit and 10 (50%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 100 across 115 interventional studies indexed under Metrorrhagia.
Median enrollment 60 across the 40 interventional studies, 300 across the 3 observational. Of the 31 that completed or were terminated, 17 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 43 have an industry lead sponsor. The 10 most frequent:
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
Icahn School of Medicine at Mount Sinai has 1 study filed under Metrorrhagia — fewer than ten, so there is no comparison to draw.
3 of the studies in Metrorrhagia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06653400Icahn School of Medicine at Mount SinaiCombined Ketorolac and Lidocaine Paracervical Block for Office Hysteroscopy | 2026-12-31 |
| NCT07290517Indiana UniversityAssessing Pain and Effectiveness of Carevix Device for IUD Insertions | 2027-03 |
| NCT07664956Christiana Care Health ServicesCyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy | 2027-05-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies in Metrorrhagia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized double-blind placebo controlled trial comparing the effect of a combined ketorolac and lidocaine paracervical block with a standard lidocaine paracervical block on procedure related pain with office hysteroscopies.
A randomized double-blind placebo controlled trial comparing the effect of a combined ketorolac and lidocaine paracervical block with a standard lidocaine paracervical block on procedure related pain with office hysteroscopies. Primary Objective: To study the effect of a combined ketorolac and lidocaine paracervical block on procedure related pain with office hysteroscopy. Secondary Objectives: To study the effect of a combined ketorolac and lidocaine paracervical block on patient satisfaction and post procedure pain. To assess for major adverse events with the use of a combined ketorolac and lidocaine paracervical block for office hysteroscopy when compared with a standard lidocaine paracervical block. Primary Endpoint: Pain on a 100 mm visual analogue scale during cervical dilation. Secondary Endpoints: Pain on a 100 mm visual analogue scale during the paracervical block, during the office hysteroscopy, immediately after the hysteroscopy, and 30 minutes after the procedure. Other secondary endpoints include patient satisfaction, frequency of procedure termination, and adverse events. Patients assigned female at birth, booked for office hysteroscopy at Mount Sinai Hospital faculty practice associates. Patients scheduled for office hysteroscopy through seeing a Gynecologist at either 5 E 98th Street Faculty Practice Associates or 1176 5th Avenue Gynecology Practice. 5 E 98th Street primarily cares for privately insured patients, while 1176 5th Avenue cares for a mix of privately insured as well as patients insured with Medicaid. Regardless of recruitment site, all office hysteroscopies will be performed at the 5 E 98th Street facility. A randomized controlled trial designed to investigate if ketorolac added to a paracervical block reduces procedure related pain. Patient will be randomized to a standard paracervical block versus a paracervical block with ketorolac added. The study will be conducted over two years. Patients will be followed for the duration of the two-year study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paracervical block will be performed with just lidocaine
Procedure: paracervical block · Drug: Lidocaine
Paracervical block will be performed with lidocaine plus ketorolac
Procedure: paracervical block · Drug: Lidocaine · Drug: ketorolac
Pain visual analogue scale (VAS)
Pain as measured on a 100 mm visual analogue scale (VAS) with cervical dilation. Full scale scored from 0-100, higher score indicates more pain.
Time frame: during procedure (cervical dilation)
Pain visual analogue scale (VAS)
Pain as measured on a 100 mm visual analogue scale (VAS). Full scale scored from 0-100, higher score indicates more pain..
Time frame: with paracervical block, during procedure, immediately after procedure, thirty minutes after the procedure
Patient Satisfaction
Full scale scored from 0-100, higher score indicates (better or poorer) health outcomes.
Time frame: with paracervical block, during procedure, immediately after procedure, thirty minutes after the procedure
Frequency of procedure termination
Number of times of procedure termination
Time frame: with paracervical block, during procedure, immediately after procedure, thirty minutes after the procedure
Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Immediately following publication. No end date.
Access criteria: Anyone who wishes to access the data. To achieve aims in the approved proposal. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Feb 2025 → Jul 2026, primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ketorolac
Icahn School of Medicine at Mount Sinai →